U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
RegulatoryapprovedTrodelvyPositive
AI Analysis
Summary
Gilead Sciences announced FDA approval of Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed therapy, for first-line treatment of metastatic triple-negative breast cancer.
Outcome Details
FDA approval for first-line treatment of metastatic triple-negative breast cancer
Importance:9/10
Sentiment:
0.95
FDA approvaloncologybreast cancerfirst-in-classTrop-2-directed
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on June 24, 2026 8:06 AM